Cambridge, Mass. - An experimental therapy that makes use of fibroblast growth factor type 1 (FGF-1) encoded in naked plasmid DNA (NV1FGF) could save the limbs of patients afflicted with chronic wounds due to critical leg ischemia associated with peripheral arterial disease (PAD), according to Vincent Li, M.D., M.B.A.
